NovoNordisk“Cagrilintide/semaglutide”Research
-ByPhcokerCagrilintideandSemaglutideoverview
WhatisCagrilintide?
Asanon-selectiveagonistforbothamylinreceptor(AMYR)andalcitoninGprotein-coupled receptor(CTR),itconfidentlyreducesfoodintake,resultinginsignificantweightloss.Cagrilintide peptideisanexcitingamylinanalogthathasshownstrongpotentialinthestudyofobesity.
CagrilintideiscurrentlybeingtestedaloneandincombinationwithSemaglutideforthetreatment ofobesityandtype2diabetes.
WhatisSemaglutide?
Semaglutideisanamazingpeptidebelongingtotheclassofmedicationsknownasglucagon-like peptide-1receptoragonists(GLP-1RAs)!Thismedicationistrulyagame-changer!Itexpertly mimicstheGLP-1hormone,significantlyincreasesinsulinrelease,effectivelylowersglucagon release,expertlydelaysgastricemptying,andgreatlyreducesappetite.
WhatisCagrilintide/semaglutide?
AfixeddosecombinationofCagrilintideandSemaglutideisunderdevelopmentforthetreatmentof type2diabetes,obesityandmetabolicdysfunction-associatedsteatohepatitis(MASH)It administeredthroughsubcutaneousroute.Cagrilintideisalong-actingamylinanaloguewhichacts bytargetingcalcitoninreceptor,receptoractivitymodifyingproteins1,2,3(RAMP1-3)and
PeptideGMPManufacturers
www.phcoker.com
semaglutideactsbytargetingglucagonlikepeptide1receptor(GLP1R).
NovoNordiskoverview
NovoNordisk,asubsidiaryofNovoHoldingsAS,isahealthcarecompanyfocusedondiscovering, developing,andmanufacturinginnovativebiologicalmedicines.Itfocusesonadvancingdrugsfor thetreatmentofdiabetesandotherseriouschronicconditions,includinghemophilia,humangrowth hormone(HGH)disorders,rarebloodandrareendocrinediseases,andobesity.
Cagrilintide/semaglutideResearches
【REDEFINE2】
AResearchStudytoSeeHowWellCagriSemaHelpsPeopleWithType2 DiabetesandExcessBodyWeightLoseWeight
BriefSummary:ThisstudywilllookathowwellthenewmedicineCagriSemahelpspeopleliving withexcessbodyweightandtype2diabeteslosingweight.ParticipantswilleithergetCagriSema oradummymedicineWhichtreatmenttheygetisdecidedbychanceItwilllastforabout15years Womencannottakepartifpregnant,breast-feedingorplanningtogetpregnantduringthestudy period
OfficialTitle:EfficacyandSafetyofCagrilintides.c.2.4mginCombinationWithSemaglutides.c. 2.4mg(CagriSemas.c.2.4mg/2.4mg)Once-weeklyinParticipantsWithOverweightorObesity andType2Diabetes
【REDEFINE3】AResearchStudytoSeetheEffectsofCagriSemainPeopleLivingWith DiseasesintheHeartandBloodVessels
BriefSummary:ThisstudywilllookattheeffectsofCagriSemaoncardiovascularevents(for exampleheartattackandstroke)inpeoplelivingwithcardiovasculardisease.Participantswill
PeptideGMPManufacturers
www.phcoker.com
eithergetCagriSemaoradummymedicine(alsocalled"placebo")whichhasnoeffectonthebody.
WhichtreatmentparticipantswillgetwillbedecidedbychanceParticipant'schanceofgetting CagriSemaorplaceboisthesameParticipantswillinjectthestudymedicineonceaweekThe studymedicinewillbeinjectedbrieflywithathinneedle,typicallyinthestomach,thighsorupper armsThestudywilllastforupto45years
OfficialTitle:TheCardiovascularSafetyandEfficacyofCagrilintide2.4mgs.c.inCombination WithSemaglutide2.4mgs.c.(CagriSema2.4mg/2.4mgs.c.)Once-weeklyinParticipantsWith EstablishedCardiovascularDisease
ThereviewofCagriSema'sresearchesprovidesacomprehensiveunderstandingofitsbackground, effects,anddevelopmentdirectionCagriSemapowderisanemergingweight-losspeptideinthe market,andonlyafewmanufacturershavemastereditsproductiontechnology.Forresearch purposes,werecommendpurchasingfromPhcoker,whichoffersGMPpharmaceutical-grade qualitytomeetyourneedsandprovidereliableanswerstoyourquestions.
WhatareresultsinClinicalTrialsofCagriSema?
CagriSemaisaonce-weeklyinjectionofsemaglutideandcagrilintidePhase2clinicaltrialresults forCagriSemashowedsignificantimprovementsinA1C,weightloss,andtimeinrange,markingit asapromisingnewtype2diabetestreatment.DevelopedbyNovoNordisk,CagriSemaisa combinationmedicationoftheGLP-1receptoragonistsemaglutideandcagrilintide.
Youmaybefamiliarwithsemaglutide(knownbyitsbrandnameOzempicfordiabetesandWegovy forweightmanagement),cagrilinitidemimicsthehormoneamylin,whichisproducedbythe pancreasTogetherwithinsulin,amylinmakespeoplefeelsatiatedorfullaftereatingameal
Resultsfromarecentphase2clinicaltrialfoundCagriSematobeapromisingcontenderasa long-lastingtreatmentfortype2diabetesgivenviaaonce-weeklyinjection.Thetrialincluded92
PeptideGMPManufacturers
www.phcoker.com
adultswhowererandomlyassignedtooneofthreetreatments:semaglutide,cagrilintide,or cagrilintideandsemaglutide
Researchersmeasuredparticipants’A1C,weight,andtimeinrangebeforestartingtreatment,and thenagainatthe32-weekmarkDosesweremaintainedatthehighestlevelforanadditional16 weeks.ThoserandomlyassignedtotheCagriSemagroupsawanA1Creductionof2.2%,weight lossof16%,andtimeinrangeimprovementsof43%.
Resultsforthetrialincluded:
AfuturetrialsponsoredbyNovoNordiskwillcomparetirzepatideandCagriSemahead-to-head, providingvaluableinsightsintotheirrelativeefficacyandsafetyprofiles.Let’slookingforwardto moreresultsinthefuture.
PeptideGMPManufacturers
www.phcoker.com
ReferencedCitations：
[1]Frias,JuanP;Deenadayalan,Srikanth;Erichsen,Lars;Knop,FilipK;Lingvay,Ildiko;Macura, Stanislava;Mathieu,Chantal;Pedersen,SueD;Davies,Melanie(August2023)"Efficacyand safetyofco-administeredonce-weeklycagrilintide2·4mgwithonce-weeklysemaglutide2·4mgin type2diabetes:amulticentre,randomised,double-blind,active-controlled,phase2trial"The Lancet.402(10403):720–730.doi:10.1016/S0140-6736(23)01163-7.PMID37364590.S2CID 259237278.
[2]Idris,Iskandar(July2023)."Coadministrationofthelong‐actingamylinanalogcagrilintideplus semaglutide(CagriSema),resultedinsignificantlygreaterweightloss,alongwithimproved measuresofglucosecontrol,inashortphase2trialofpatientswithtype2diabetes"Diabetes, ObesityandMetabolismNow1(7)doi:101002/doi268ISSN2688-8939
[3]Holst,JensJuul;Jepsen,SaraLind;Modvig,Ida(April2022)"GLP-1–Incretinandpleiotropic hormonewithpharmacotherapypotential.IncreasingsecretionofendogenousGLP-1fordiabetes andobesitytherapy".CurrentOpinioninPharmacology.63:102189. doi:10.1016/j.coph.2022.102189.PMID35231672.
[4]Jeon,Eonju;Lee,KiYoung;Kim,Kyoung-Kon(1June2023)."ApprovedAnti-Obesity Medicationsin2022KSSOGuidelinesandthePromiseofPhase3ClinicalTrials:Anti-Obesity DrugsintheSkyandontheHorizon"JournalofObesity&MetabolicSyndrome32(2):106–120 doi:107570/jomes23032ISSN2508-7576PMC10327684PMID37349257
[5]Enebo,LoneB;Berthelsen,KasperK;Kankam,Martin;Lund,MichaelT;Rubino,DomenicaM; Satylganova,Altynai;Lau,DavidCW(May2021)."Safety,tolerability,pharmacokinetics,and pharmacodynamicsofconcomitantadministrationofmultipledosesofcagrilintidewithsemaglutide 24mgforweightmanagement:arandomised,controlled,phase1btrial".TheLancet.397(10286): 1736–1748doi:101016/S0140-6736(21)00845-XPMID33894838S2CID233354744
[6]Larsen,AT;Mohamed,KE;Sonne,N;Bredtoft,E;Andersen,F;Karsdal,MA;Henriksen, K(1December2022)“Doesreceptorbalancematter?–Comparingtheefficaciesofthedual amylinandcalcitoninreceptoragonistscagrilintideandKBP-336onmetabolicparametersin preclinicalmodels“.Biomedicine&Pharmacotherapy.156:113842.
doi:10.1016/j.biopha.2022.113842.ISSN0753-3322.PMID36242844.S2CID252881350
[7]Enebo,LoneB;Berthelsen,KasperK;Kankam,Martin;Lund,MichaelT;Rubino,DomenicaM; Satylganova,Altynai;Lau,DavidCW(May2021)“Safety,tolerability,pharmacokinetics,and pharmacodynamicsofconcomitantadministrationofmultipledosesofcagrilintidewithsemaglutide 2·4mgforweightmanagement:arandomised,controlled,phase1btrial“TheLancet397(10286): 1736–1748doi:101016/S0140-6736(21)00845-XPMID33894838S2CID233354744
[8]Idris,Iskandar(July2023).“Coadministrationofthelong‐actingamylinanalogcagrilintideplus semaglutide(CagriSema),resultedinsignificantlygreaterweightloss,alongwithimproved measuresofglucosecontrol,inashortphase2trialofpatientswithtype2diabetes“.Diabetes, ObesityandMetabolismNow1(7)doi:101002/doi268ISSN2688-8939
[9]Holst,JensJuul;Jepsen,SaraLind;Modvig,Ida(April2022)“GLP-1–Incretinandpleiotropic hormonewithpharmacotherapypotentialIncreasingsecretionofendogenousGLP-1fordiabetes andobesitytherapy“CurrentOpinioninPharmacology63:102189 doi:10.1016/j.coph.2022.102189.PMID3523167
[10]Jeon,Eonju;Lee,KiYoung;Kim,Kyoung-Kon(1June2023).“ApprovedAnti-Obesity Medicationsin2022KSSOGuidelinesandthePromiseofPhase3ClinicalTrials:Anti-Obesity DrugsintheSkyandontheHorizon“.JournalofObesity&MetabolicSyndrome.32(2):106–doi:107570/jomes23032ISSN2508-7576PMC10327684PMID37349257
[11]ChristouGA,KatsikiN,BlundellJ,FruhbeckG,KiortsisDN”Semaglutideasapromising antiobesitydrug”ObesRev2019Jun;20(6):805-815doi:101111/obr12839Epub2019Feb 15PMID:30768766
[12]MeierJJ.”EfficacyofSemaglutideinaSubcutaneousandanOralFormulation.”Front Endocrinol(Lausanne).2021Jun25;12:645617.doi:10.3389/fendo.2021.645617.eCollection 2021.PMID:34248838
[13]GarveyWT,BatterhamRL,BhattaM,BuscemiS,ChristensenLN,FriasJP,JódarE,KandlerK, RigasG,WaddenTA,WhartonS;STEP5StudyGroup”Two-yeareffectsofsemaglutideinadults withoverweightorobesity:theSTEP5trial”NatMed2022Oct;28(10):2083-2091doi: 101038/s41591-022-02026-4Epub2022Oct10PMID:36216945
[14]HusainM,BirkenfeldAL,DonsmarkM,DunganK,EliaschewitzFG,FrancoDR,JeppesenOK, LingvayI,MosenzonO,PedersenSD,TackCJ,ThomsenM,VilsbøllT,WarrenML,BainSC;
PIONEER6Investigators.”OralSemaglutideandCardiovascularOutcomesinPatientswithType2
Diabetes”NEnglJMed2019Aug29;381(9):841-851doi:101056/NEJMoa1901118Epub2019
Jun11PMID:31185157
[15]WildingJPH,BatterhamRL,DaviesM,VanGaalLF,KandlerK,KonakliK,LingvayI, McGowanBM,OralTK,RosenstockJ,WaddenTA,WhartonS,YokoteK,KushnerRF;STEP1 StudyGroup.”Weightregainandcardiometaboliceffectsafterwithdrawalofsemaglutide:The STEP1trialextension.”DiabetesObesMetab.2022Aug;24(8):1553-1564.doi:10.1111/dom.14725.
Epub2022May19.PMID:35441470
Authorofthisarticle:
DrJeanZenggraduatedfromking’scollegelondonFacultyofLifeSciences&Medicine
ScientificJournalpaperAuthor:
1.CarolineMApovian
BrighamandWomen'sHospital,HarvardMedicalSchool,Boston,MA02115,USA
2MarieEMcDonnell
BrighamandWomen'sHospital,HarvardMedicalSchool,Boston,MA02115,USA
3JuanPFriasMD
Correspondenceto:DrJuanPFrias,VelocityClinicalResearch,LosAngeles,CA90057,USA
PeptideGMPManufacturers
www.phcoker.com